Top Markets
Coin of the day
AIM Vaccine Co., Ltd. AIM Vaccine Co., Ltd.

AIM Vaccine Co., Ltd.

6660
Rang in Aktien #16632
Operating within the People's Republic of China, AIM Vaccine Co., Ltd.... Operating within the People's Republic of China, AIM Vaccine Co., Ltd. specializes in the entire lifecycle of human vaccine products, encompassing their discovery, production, and market introduction. Among its current developments, the company is advancing Bivalent Delta-Omicron BA.5 mRNA and Monovalent Omicron BA.5 mRNA vaccine candidates for COVID-19, both currently undergoing Phase III clinical trials. Its comprehensive portfolio also features vaccines targeting a range of other conditions, such as an EV71-CA16 Bivalent vaccine for Hand, Foot, and Mouth Disease (HFMD), and both Conjugate and Polysaccharide versions for pneumococcal disease. Further offerings include a Hexavalent group B Streptococcus Polysaccharide Conjugate Vaccine, various Diphtheria, Tetanus, and Pertussis (DTP) formulations (including DTP combined with Haemophilus Influenzae type B, acellular pertussis, and absorbed tetanus), a Haemophilus Influenzae Type B (Hib) vaccine, and both traditional freeze-dried and innovative mRNA human rabies vaccines. Beyond these, AIM Vaccine is actively developing several other vaccines, including 2- and 3-valent Human Papillomavirus (HPV) vaccines, a Tetravalent Meningococcal Conjugate vaccine, a Tetravalent Influenza vaccine, mRNA-based vaccines for Shingles/Herpes Zoster and Respiratory Syncytial Virus (RSV), a live attenuated parotitis vaccine, and an ACYW135 meningococcal polysaccharide vaccine. Established in 2011 and headquartered in Beijing, PRC, the company adopted its current name, AIM Vaccine Co., Ltd., in September 2020, having previously operated as Beijing AIM Biological Vaccine Technology Group Co., Ltd.
Aktienkurs
$0.23026721
Marktkapitalisierung
$281.95M
Veränderung (1 Tag)
4.96%
Veränderung (1 Jahr)
-64.40%
Land
CN
Handel AIM Vaccine Co., Ltd. (6660)

Kategorie

Preis 6660 mit Marktkapitalisierung von B
AIM Vaccine Co., Ltd. AIM Vaccine Co., Ltd.
6660
$0.23026721
Marktkapitalisierung von AIM Vaccine Co., Ltd.(6660)
Marktkapitalisierung: $281.95M
Mit Stand September 2026 hat AIM Vaccine Co., Ltd. eine Marktkapitalisierung von $281.95M. Das macht AIM Vaccine Co., Ltd. laut unseren Daten zum 16632nd wertvollsten Unternehmen der Welt nach Marktkapitalisierung. Die Marktkapitalisierung ist der Gesamtmarktwert aller ausstehenden Aktien eines börsennotierten Unternehmens und wird häufig verwendet, um den Unternehmenswert zu bestimmen.
Marktkapitalisierung von AIM Vaccine Co., Ltd. von 2022 bis 2026
6660 im Vergleich zu den Top 5 der beliebtesten stocks
Preis für 6660 Vermögenswert B Marktkapitalisierung von B Ergebnisse
AIM Vaccine Co., Ltd. AIM Vaccine Co., Ltd.
$4,295.50 $281.95M
$5.260T +1,865,341.47%
AIM Vaccine Co., Ltd. AIM Vaccine Co., Ltd.
$3,902.61 $281.95M
$4.779T +1,694,716.02%
AIM Vaccine Co., Ltd. AIM Vaccine Co., Ltd.
$3,280.45 $281.95M
$4.017T +1,424,529.55%
AIM Vaccine Co., Ltd. AIM Vaccine Co., Ltd.
$3,037.54 $281.95M
$3.719T +1,319,038.63%
AIM Vaccine Co., Ltd. AIM Vaccine Co., Ltd.
$2,233.04 $281.95M
$2.734T +969,660.97%